Người mắc bệnh tiểu đường type 2 (T2DM) có nguồn gốc Bangladesh với kiểu hình acetyl hóa nhanh N-acetyltransferase 2 (NAT2) cho thấy độ nhạy insulin thấp hơn so với kiểu hình acetyl hóa chậm

King H, Aubert RE, Herman WH. Global burden of diabetes 1995–2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414–31. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787–94. Zimmet P. Type 2 (noninsulin-dependent) diabetes: an epidemiological overview. Diabetologia. 1982;22:399–411. Lyssenko V, Jonsson A, Almgren P. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220–32. Hein DW, Doll MA, Rustan TD. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and—polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993;14:1633–8. Hein DW, Doll MA, Fretland AJ. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;9:29–42. Hickman D, Risch A, Buckle V, Spurr N, Jeremiah SJ, McCarthy A, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J. 1994;297:441–5. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant M, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 2000;54:19–29. Anderson KE, Hammons GJ, Kadlubar FF, Potter JD, Kaderlik KR, Ileutt KF, et al. Metabolic activation of aromatic amines by human pancreas. Carcinogenesis. 1997;18:1085–92. Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2002;2:30–42. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9:193–203. Weber WW, Hein DW. N-Acetylation pharmacogenetics. Pharmacol Rev. 1985;37:25–79. Evans DAP. N-acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 95–178. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N- acetyltransferase. Enzymatic analysis of 15 recombinant wildtype, mutant, and chimeric NAT2 allozymes. Hum Mol Genet. 1994;3:729–34. Bodansky HJ, Drury PL, Cudworth AG, Evans DAP. Acetylator phenotypes and type 1 (insulin-dependent) diabetics with microvascular disease. Diabetes. 1981;30:907–10. Korpinen E, Groop PH, Rautio A. N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy. Pharmacogenetics. 1999;9:627–33. Agundez JA, Menaya JG, Tejeda R, Lago F, Chavez M, Benitez J. Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Pharmacogenetics. 1996;6:465–72. Hegele RA, Kwan K, Harris SB, Hanley AJ, Zinman B, Cao H. NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. Pharmacogenetics. 2000;10:233–8. Yalin S, Hatungil R, Tamer L, Ates NA, Dogruer N, Yildirim H, et al. N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. Cell Biochem Funct. 2007;25:407–11. Report of a WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classificaton of diabetes mellitus. In: Current WHO publications on diabetes. World Health Organization. 1999. http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2. Inatomi H, Katoh K, Kawamoto T, Matsumoto T. NAT 2 gene polymorphism as a possible biomarker for susceptibility to bladder cancer in Japanese. Int J Urol. 1999;6:446–54. Borlak J, Marie Reamon-Buettner S. N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson’s disease. BMC Med Genet. 2006;7:30–4. McLaren EH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathy. Br Med J. 1977;2:291–3. Shenfield GM, McCann VJ, Tjokresetio R. Acetylator status and diabetic neuropathy. Diabetologia. 1982;22:441–4. Pontiroli AE, Mosca A, de Pasqua A, Alcini D, Pozza G. The fast acetylator phenotype in diabetes mellitus: abnormal prevalence and association with the ABO blood groups. Diabetologia. 1984;27:235–7. Evans DAP, Paterson S, Fransisco P, Alvarege G. The acetylator phenotypes of Saudi Arabian diabetics. J Med Genet. 1985;22:479–83. Madacsy L, Szorady I, Santa A, Barkai L, Vamosi I. Association of microalbuminuria with slow acetylator phenotype in type 1 diabetes mellitus. Child Nephrol Urol. 1992;12:192–6. Semiz S, Dujic T, Ostanek B, Velija-Asimi Z, Prnjavorac B, Bego T, et al. Association of NAT2 polymorphisms with type 2 diabetes in a population from Bosnia and Herzegovina. Arch Med Res. 2011;42:311–7. Neugebauer S, Baba T, Watanabe T, Ishizaki T, Kurokawa K. The N-acetyltransferase (NAT) gene: an early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients? Diabet Med. 1994;11:783–8. Notkins AL. Immunologic and genetic factors in type 1 diabetes. Biol Chem. 2002;277:43545–8.